FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100304874> ?p ?o ?g. }

• W2100304874 endingPage "94" @default.
• W2100304874 startingPage "588" @default.
• W2100304874 abstract "Gemcitabine (dFdC) is a new nucleoside antimetabolite of deoxycytidine that resembles cytarabine (Ara-C) in both its structure and metabolism. Little is known about dFdC efficacy in hematologic malignancies, either as a single drug or in combination with other drugs. In this study we have tried to determine whether the cytotoxic effect of Ara-C can be increased by using it in combined therapy with dFdC.In the in vivo part of our study, mice bearing L1210 or P388 leukemia were treated with dFdC and Ara-C. The drugs were administered alone and in combination according to the following schedules: Ara-C and dFdC at the same time, dFdC before Ara-C, and Ara-C before dFdC. The efficacy of the therapy against leukemia (defined as the increase in lifespan, ILS) was assessed as the percentage of the median survival time (MST) of the treated group (T) in relationship to that of the control group (C): ILS=[(MST(C)/MST(T)) -1]x100. In the in vitro part of our study, normal granulocyte-macrophage colony-forming unit (CFU-GM) cells as well as CFU-GM cells obtained from patients with chronic myeloid leukemia (CML) were incubated either with dFdC or Ara-C alone or with adequate concentrations of a combination of these drugs.The in vivo experiment revealed that in both leukemias tested, combined therapy with dFdC given before Ara-C and dFdC given at the same time with Ara-C were more effective than monotherapy with either dFdC or Ara-C. The other treatment schedule (Ara-C before dFdC) did not significantly prolong the survival time of the treated mice bearing L1210 or P388 leukemia as compared with the treatment with dFdC alone. The in vitro experiments showed that dFdC used together with Ara-C acted additively on normal as well as CML CFU-GM cells. Furthermore, the drugs used jointly inhibited the growth of colonies formed by CML CFU-GM cells to a significantly higher degree than normal CFU-GM and the differences were statistically significant in the case of the combination of highest concentrations.Gemcitabine increased the activity of Ara-C. As these agents incorporate into DNA blocking chain elongation, and moreover, dFdC influences the cytotoxicity of Ara-C, our results could be explained by the drugs acting at these levels. dFdC used jointly with Ara-C may have an important clinical implication in the treatment of CML and other hematologic malignancies in future." @default.
• W2100304874 created "2016-06-24" @default.
• W2100304874 creator A5022628384 @default.
• W2100304874 creator A5026001978 @default.
• W2100304874 creator A5069332579 @default.
• W2100304874 date "2000-06-01" @default.
• W2100304874 modified "2023-09-23" @default.
• W2100304874 title "The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro." @default.
• W2100304874 cites W1527742565 @default.
• W2100304874 cites W1819781110 @default.
• W2100304874 cites W1979744341 @default.
• W2100304874 cites W1995433735 @default.
• W2100304874 cites W2007640889 @default.
• W2100304874 cites W2009974957 @default.
• W2100304874 cites W2012432138 @default.
• W2100304874 cites W2029258363 @default.
• W2100304874 cites W2034373046 @default.
• W2100304874 cites W2042010784 @default.
• W2100304874 cites W2047435984 @default.
• W2100304874 cites W2047692316 @default.
• W2100304874 cites W2060042269 @default.
• W2100304874 cites W2068345231 @default.
• W2100304874 cites W2090849472 @default.
• W2100304874 cites W2092569103 @default.
• W2100304874 cites W2118512375 @default.
• W2100304874 cites W2124482385 @default.
• W2100304874 cites W2154037033 @default.
• W2100304874 cites W2168555194 @default.
• W2100304874 cites W2189806579 @default.
• W2100304874 cites W2270132162 @default.
• W2100304874 cites W2284799106 @default.
• W2100304874 cites W2288894655 @default.
• W2100304874 cites W2300371971 @default.
• W2100304874 cites W2397570806 @default.
• W2100304874 cites W2408911182 @default.
• W2100304874 cites W2409210411 @default.
• W2100304874 cites W2462077090 @default.
• W2100304874 cites W85534417 @default.
• W2100304874 cites W887811850 @default.
• W2100304874 cites W2525668928 @default.
• W2100304874 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10870114" @default.
• W2100304874 hasPublicationYear "2000" @default.
• W2100304874 type Work @default.
• W2100304874 sameAs 2100304874 @default.
• W2100304874 citedByCount "4" @default.
• W2100304874 countsByYear W21003048742018 @default.
• W2100304874 crossrefType "journal-article" @default.
• W2100304874 hasAuthorship W2100304874A5022628384 @default.
• W2100304874 hasAuthorship W2100304874A5026001978 @default.
• W2100304874 hasAuthorship W2100304874A5069332579 @default.
• W2100304874 hasConcept C126322002 @default.
• W2100304874 hasConcept C150903083 @default.
• W2100304874 hasConcept C185592680 @default.
• W2100304874 hasConcept C202751555 @default.
• W2100304874 hasConcept C203014093 @default.
• W2100304874 hasConcept C207001950 @default.
• W2100304874 hasConcept C2776543447 @default.
• W2100304874 hasConcept C2776694085 @default.
• W2100304874 hasConcept C2777333352 @default.
• W2100304874 hasConcept C2777844706 @default.
• W2100304874 hasConcept C2778041864 @default.
• W2100304874 hasConcept C2778397455 @default.
• W2100304874 hasConcept C2778461978 @default.
• W2100304874 hasConcept C2779268695 @default.
• W2100304874 hasConcept C2780258809 @default.
• W2100304874 hasConcept C502942594 @default.
• W2100304874 hasConcept C55493867 @default.
• W2100304874 hasConcept C71924100 @default.
• W2100304874 hasConcept C86803240 @default.
• W2100304874 hasConcept C98274493 @default.
• W2100304874 hasConceptScore W2100304874C126322002 @default.
• W2100304874 hasConceptScore W2100304874C150903083 @default.
• W2100304874 hasConceptScore W2100304874C185592680 @default.
• W2100304874 hasConceptScore W2100304874C202751555 @default.
• W2100304874 hasConceptScore W2100304874C203014093 @default.
• W2100304874 hasConceptScore W2100304874C207001950 @default.
• W2100304874 hasConceptScore W2100304874C2776543447 @default.
• W2100304874 hasConceptScore W2100304874C2776694085 @default.
• W2100304874 hasConceptScore W2100304874C2777333352 @default.
• W2100304874 hasConceptScore W2100304874C2777844706 @default.
• W2100304874 hasConceptScore W2100304874C2778041864 @default.
• W2100304874 hasConceptScore W2100304874C2778397455 @default.
• W2100304874 hasConceptScore W2100304874C2778461978 @default.
• W2100304874 hasConceptScore W2100304874C2779268695 @default.
• W2100304874 hasConceptScore W2100304874C2780258809 @default.
• W2100304874 hasConceptScore W2100304874C502942594 @default.
• W2100304874 hasConceptScore W2100304874C55493867 @default.
• W2100304874 hasConceptScore W2100304874C71924100 @default.
• W2100304874 hasConceptScore W2100304874C86803240 @default.
• W2100304874 hasConceptScore W2100304874C98274493 @default.
• W2100304874 hasIssue "6" @default.
• W2100304874 hasLocation W21003048741 @default.
• W2100304874 hasOpenAccess W2100304874 @default.
• W2100304874 hasPrimaryLocation W21003048741 @default.
• W2100304874 hasRelatedWork W1902196118 @default.
• W2100304874 hasRelatedWork W1978805491 @default.
• W2100304874 hasRelatedWork W2014245211 @default.
• W2100304874 hasRelatedWork W2087011085 @default.

• next